Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Blood|May 23, 2008
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemiaGuillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialFranck Morschhauser, Hervé Tilly, Aristeidis Chaidos, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
JAMA|February 18, 2015
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
The New England Journal of Medicine|March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
The Lancet. Oncology|July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Nature|May 30, 2014
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidationHiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Sarit Assouline, et al.
American Journal of Hematology|March 20, 2026
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary AnalysisNancy L Bartlett, Laurie H Sehn, Sarit Assouline, et al.
Pageof 9